BeOne Medicines Ltd. — Director's Dealing 2022

Sep 8, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BeiGene, Ltd. (BGNE)
CIK: 0001651308
Period of Report: 2022-09-06

Reporting Person: Wang Xiaodong (Director, Chair, Scientific Advisory Brd)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-09-06	Ordinary Shares	G	33410	—	Disposed	5629556	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Ordinary Shares	1127542	Indirect
Ordinary Shares	172372	Indirect
Ordinary Shares	4188998	Indirect
Ordinary Shares	50	Indirect

Footnotes

F1: Bona fide gift(s) of shares which are exempt from Section 16(b) of the Securities Exchange Act pursuant to Rule 16b-5.

F2: These securities are held by a family trust, the beneficiaries of which are the Reporting Person's family members, for which the Reporting Person disclaims beneficial ownership.

F3: These securities are held in a UTMA account for the Reporting Person's child, for which the Reporting Person disclaims beneficial ownership.

F4: These securities are held by Wang Investment LLC, of which 99% of the limited liability company interest is owned by two grantor retained annuity trusts, of which the Reporting Person's wife is a trustee, for which the Reporting Person disclaims beneficial ownership.

F5: These securities are held by the spouse of the Reporting Person.